<?xml version="1.0" encoding="UTF-8" ?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>EAU News</title><link>http://www.uroweb.org</link><description>European Association of Urology</description><atom:link href="http://www.uroweb.org/rss.xml" rel="self" type="application/rss+xml" /><item><title><![CDATA[Stockholm to host 10th Anniversary ERUS Meeting]]></title><link><![CDATA[http://www.uroweb.org/?id=23&act=showfull&aid=665]]></link><guid><![CDATA[http://www.uroweb.org/news/?act=showfull&aid=665]]></guid><description><![CDATA[The EAU Robotic Urology Section (ERUS), formerly a non-affiliated society, will hold in Stockholm, Sweden the 10th anniversary of its yearly congress. It all started back in 2004 in Paris with about 50 participants, and since then the ERUS Congress has grown steadily with last year’s meeting in London attracting over 900 participants. For the second time in its history, Stockholm will host the ERUS meeting on September 3 to 5, 2013.]]></description></item><item><title><![CDATA[250th Patient screened in EAU Research Foundation's Magnolia Trial]]></title><link><![CDATA[http://www.uroweb.org/?id=23&act=showfull&aid=661]]></link><guid><![CDATA[http://www.uroweb.org/news/?act=showfull&aid=661]]></guid><description><![CDATA[The MAGNOLIA study is a double-blind phase II trial which evaluates the safety and efficacy of antigen-specific cancer immunotherapy with recMAGE-A3 + AS15 in patients with muscle-invasive bladder cancer. This non-commercial study is the first European bladder cancer study sponsored by the EAU Research Foundation, and the only European study evaluating antigen-specific immunotherapy in patients after cystectomy. The study has started in 36 sites in around Europe. New sites from Romania, Ukraine and Russia will be initiated in the next month.]]></description></item><item><title><![CDATA[Survey: benign prostatic obstruction and laser treatment]]></title><link><![CDATA[http://www.uroweb.org/?id=23&act=showfull&aid=660]]></link><guid><![CDATA[http://www.uroweb.org/news/?act=showfull&aid=660]]></guid><description><![CDATA[The Benign Prostatic Hyperplasia (BPH) group of the Young Academic Urologists (YAU) of the EAU is conducting a survey among European urologists, on the management of patients with benign prostatic obstruction (BPO) with a particular interest on the use of laser technologies. Although different laser technologies and laser procedures have been introduced in the last decade for the management of BPO, the standard laser treatment for these patients is still to be defined.]]></description></item><item><title><![CDATA[Report: Live reconstructive surgery and expert speakers at 3rd ESGURS Section Meeting in Istanbul]]></title><link><![CDATA[http://www.uroweb.org/?id=23&act=showfull&aid=658]]></link><guid><![CDATA[http://www.uroweb.org/news/?act=showfull&aid=658]]></guid><description><![CDATA[Leading European experts active reconstruction surgeons of genito-urinary system in urology gathered in Istanbul in 14-15th December 2012 to discuss the latest advances and applications in the field. The 3rd meeting of the EAU Section of Genito-Urinary Reconstructive Surgery (ESGURS) met many of our expectations and more. All the presentations and live surgeries were of excellent quality, which resulted in excellent interaction and discussion between speakers and the audience throughout the meeting.]]></description></item><item><title><![CDATA[Post-congress reflections: Prof. Manfred Wirth looks back on Milan]]></title><link><![CDATA[http://www.uroweb.org/?id=23&act=showfull&aid=656]]></link><guid><![CDATA[http://www.uroweb.org/news/?act=showfull&aid=656]]></guid><description><![CDATA[At the 28th Annual EAU Congress in Milan, the Scientific Congress Office has again presented a programme whose format, coverage and contents reflected the intense and careful preparations which are necessary for a high quality international meeting.]]></description></item><item><title><![CDATA[Reconsidering metal stenting of the upper urinary tract at the pre-conference symposium at the 2nd EULIS Meeting]]></title><link><![CDATA[http://www.uroweb.org/?id=23&act=showfull&aid=655]]></link><guid><![CDATA[http://www.uroweb.org/news/?act=showfull&aid=655]]></guid><description><![CDATA[The new generation of metal stents has several advantages over plastic stents, and urologists need to be aware of the long-term benefits. The EAU Section of Urolithiasis (EULIS) is holding its second annual meeting in Copenhagen on 5-7 September. The meeting will be preceded on September 4th by the 1st International Symposium on Metal Stenting of the Upper Urinary Tract.]]></description></item><item><title><![CDATA[Thank you for coming!]]></title><link><![CDATA[http://www.uroweb.org/?id=23&act=showfull&aid=652]]></link><guid><![CDATA[http://www.uroweb.org/news/?act=showfull&aid=652]]></guid><description><![CDATA[<img src='http://uroweb.org/deposit/1621/staff_pic.jpg?1363688873' style='width:100%;'>
<br><br>
Thanks to all for coming to Milan, sharing 5 wonderful days with us, following us on Twitter and Facebook, reading updates on the Congress website. See you next year in Stockholm!]]></description></item><item><title><![CDATA[European views on PSA screening debate]]></title><link><![CDATA[http://www.uroweb.org/?id=23&act=showfull&aid=654]]></link><guid><![CDATA[http://www.uroweb.org/news/?act=showfull&aid=654]]></guid><description><![CDATA[The controversial debate regarding the benefits and harms of PSA screening for prostate cancer took centre stage in the concluding plenary session of the 28th Annual EAU Congress held in Milan last Tuesday.]]></description></item><item><title><![CDATA[Genetics, age and ethnicity are risk factors in prostate cancer, say experts]]></title><link><![CDATA[http://www.uroweb.org/?id=23&act=showfull&aid=653]]></link><guid><![CDATA[http://www.uroweb.org/news/?act=showfull&aid=653]]></guid><description><![CDATA[Genetics, age and ethnicity are risk factors for prostate cancer, while the evidence for obesity, smoking and diabetes as associated risks remains uncertain, according to prostate cancer experts.]]></description></item><item><title><![CDATA[ZEUS study yields no survival benefits and positive results]]></title><link><![CDATA[http://www.uroweb.org/?id=23&act=showfull&aid=648]]></link><guid><![CDATA[http://www.uroweb.org/news/?act=showfull&aid=648]]></guid><description><![CDATA[The initial study results of the Zometa European Study (ZEUS) showed no difference in the incidence of bone metastases between the Zometa group and control arm, said Prof. Manfred Wirth during the closing and fourth plenary session of the 28th Annual EAU Congress which ends today.]]></description></item></channel></rss>